CU20170089A7 - Derivados de quinazolina utilizados para tratar el vih - Google Patents

Derivados de quinazolina utilizados para tratar el vih

Info

Publication number
CU20170089A7
CU20170089A7 CUP2017000089A CU20170089A CU20170089A7 CU 20170089 A7 CU20170089 A7 CU 20170089A7 CU P2017000089 A CUP2017000089 A CU P2017000089A CU 20170089 A CU20170089 A CU 20170089A CU 20170089 A7 CU20170089 A7 CU 20170089A7
Authority
CU
Cuba
Prior art keywords
derivatives used
quinazoline derivatives
treat hiv
compounds
formula
Prior art date
Application number
CUP2017000089A
Other languages
English (en)
Inventor
Ondrej Baszczynski
Milian Dejmek
Yunfeng Eric Hu
Petr Jansa
Eric Lansdon
Richard L Mackman
Petr Simon
Original Assignee
Gilead Sciences Inc
Inst Of Organic Chemistry And Biochemistry Of The As Cr V V I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Inst Of Organic Chemistry And Biochemistry Of The As Cr V V I filed Critical Gilead Sciences Inc
Publication of CU20170089A7 publication Critical patent/CU20170089A7/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>Se describen en el presente documento compuestos de Formula (I)</p> <p>ESPACIO PARA FÓRMULA</p> <p>y tautómeros y sales farmacéuticas de los mismos, métodos para prepararlos, composiciones y formulaciones que contienen dichos compuestos, los cuales son útiles en el tratamiento y prevención de infección por VIH en un sujeto.<br />  </p>
CUP2017000089A 2014-12-24 2015-12-23 Derivados de quinazolina utilizados para tratar el vih CU20170089A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462096748P 2014-12-24 2014-12-24
PCT/US2015/000460 WO2016105564A1 (en) 2014-12-24 2015-12-23 Quinazoline derivatives used to treat hiv

Publications (1)

Publication Number Publication Date
CU20170089A7 true CU20170089A7 (es) 2017-11-07

Family

ID=55305044

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2017000089A CU20170089A7 (es) 2014-12-24 2015-12-23 Derivados de quinazolina utilizados para tratar el vih

Country Status (41)

Country Link
US (5) US9730936B2 (es)
EP (4) EP3521282B1 (es)
JP (2) JP6367489B2 (es)
KR (2) KR102288855B1 (es)
CN (2) CN111574464A (es)
AR (1) AR103252A1 (es)
AU (1) AU2015371198B2 (es)
BR (1) BR102015032361B1 (es)
CA (1) CA2972021C (es)
CL (1) CL2017001675A1 (es)
CO (1) CO2017006214A2 (es)
CR (1) CR20170281A (es)
CU (1) CU20170089A7 (es)
CY (1) CY1124726T1 (es)
DK (1) DK3521282T3 (es)
DO (1) DOP2017000151A (es)
EA (2) EA202091115A1 (es)
EC (1) ECSP17039611A (es)
ES (3) ES2715507T3 (es)
HK (1) HK1244001B (es)
HR (1) HRP20211543T1 (es)
HU (1) HUE058296T2 (es)
IL (2) IL253059B (es)
LT (1) LT3521282T (es)
MA (1) MA48448A (es)
MD (1) MD4650B1 (es)
MX (2) MX367574B (es)
MY (1) MY189761A (es)
NZ (1) NZ733174A (es)
PE (1) PE20171306A1 (es)
PH (1) PH12017501191B1 (es)
PL (3) PL3521282T3 (es)
PT (2) PT3237398T (es)
SA (1) SA517381826B1 (es)
SG (2) SG11201705215PA (es)
SI (2) SI3521282T1 (es)
SV (1) SV2017005471A (es)
TR (1) TR201903672T4 (es)
TW (3) TWI770552B (es)
UA (1) UA117796C2 (es)
WO (1) WO2016105564A1 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
AU2015371255B2 (en) 2014-12-24 2018-09-27 Gilead Sciences, Inc. Fused pyrimidine compounds for the treatment of HIV
JP6356919B2 (ja) 2014-12-24 2018-07-11 ギリアード サイエンシーズ, インコーポレイテッド Hivの処置のためのイソキノリン化合物
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
SI3347352T1 (sl) 2016-08-19 2019-08-30 Gilead Sciences, Inc. Terapevtske spojine uporabne za profilaktično ali terapevtsko zdravljenje okužbe z virusom HIV
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
FI3706762T3 (fi) 2017-12-07 2024-12-13 Univ Emory N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ, インコーポレイテッド ピリジン誘導体およびhiv感染を処置するためのその使用
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
WO2019204768A1 (en) * 2018-04-20 2019-10-24 The Regents Of The University Of California Beta-adrenergic receptor allosteric modulators
CA3103522C (en) 2018-07-16 2023-11-21 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
CA3124569A1 (en) 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
LT3938047T (lt) 2019-03-22 2022-10-10 Gilead Sciences, Inc. Tilteliniai tricikliniai karbamoilpiridono junginiai ir jų naudojimas farmacijoje
US20200347036A1 (en) 2019-04-17 2020-11-05 Gilead Sciences, Inc. Solid forms of an hiv protease inhibitor
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
TW202519228A (zh) 2019-11-26 2025-05-16 美商基利科學股份有限公司 預防hiv之蛋白殼抑制劑
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
KR20230005827A (ko) 2020-04-24 2023-01-10 스미토모 파마 가부시키가이샤 2-헤테로아릴아미노퀴나졸리논 유도체
EP4172157B1 (en) 2020-06-25 2025-11-19 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
EP4660325A3 (en) 2020-11-11 2026-02-25 Gilead Sciences, Inc. Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
PL4445900T3 (pl) 2021-12-03 2025-09-22 Gilead Sciences, Inc. Związki terapeutyczne przeciwko zakażeniu wirusem hiv
KR20240113832A (ko) 2021-12-03 2024-07-23 길리애드 사이언시즈, 인코포레이티드 Hiv 바이러스 감염 치료용 화합물
WO2023102529A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024006982A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
KR20250051732A (ko) 2022-08-26 2025-04-17 길리애드 사이언시즈, 인코포레이티드 광범위 중화 항체를 위한 투여 및 일정 요법
US20240226130A1 (en) 2022-10-04 2024-07-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
CN121358478A (zh) 2023-04-19 2026-01-16 吉利德科学公司 衣壳抑制剂的给药方案
WO2024249592A1 (en) 2023-05-31 2024-12-05 Gilead Sciences, Inc. Quinazolinyl-indazole derivatives as therapeutic compounds for hiv
US20250011352A1 (en) 2023-05-31 2025-01-09 Gilead Sciences, Inc. Solid forms
KR102928747B1 (ko) 2023-07-21 2026-02-26 대한민국 피라졸로[1,5-에이]퀴나졸린 유도체 화합물을 포함하는 인간면역결핍바이러스 억제용 조성물
AU2023460182A1 (en) 2023-07-28 2026-02-05 Gilead Sciences, Inc. Weekly regimen of lenacapavir for the treatment and prevention of hiv
AU2023462614A1 (en) 2023-08-23 2026-03-19 Gilead Sciences, Inc. Dosing regimen of hiv capsid inhibitor
WO2025080850A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080879A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202530227A (zh) 2023-10-11 2025-08-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20250230163A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
WO2025184609A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Antiviral compounds
WO2025184447A1 (en) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
US20250289822A1 (en) 2024-03-01 2025-09-18 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
US20260007683A1 (en) 2024-06-14 2026-01-08 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ197420A (en) 1980-07-01 1984-04-27 Ici Australia Ltd -(quinazolin-(2-or 4-)(oxy,ylthio or amino)phen(oxy or ylthio)alkanoic acid derivatives
JPH11209350A (ja) 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
ES2270867T3 (es) * 1999-09-23 2007-04-16 Astrazeneca Ab Compuestos de quinazolina terapeuticos.
AU1462101A (en) 1999-11-22 2001-06-04 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
GB0002032D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
AU2001275724A1 (en) 2000-08-02 2002-02-13 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
US7547702B2 (en) 2000-09-20 2009-06-16 Ortho-Mcneil Pharmaceutical, Inc. 4-amino-quinazolines
AU2003255482A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
WO2004108711A1 (en) 2003-06-05 2004-12-16 Astrazeneca Ab Pyrazinil quinazoline derivatives for use in the treatment of tumours
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
PL216369B1 (pl) 2004-07-27 2014-03-31 Gilead Sciences Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
WO2006045828A1 (en) 2004-10-29 2006-05-04 Tibotec Pharmaceuticals Ltd. Hiv inhibiting bicyclic pyrimidine derivatives
JP2008526734A (ja) 2004-12-31 2008-07-24 エスケー ケミカルズ カンパニー リミテッド 糖尿及び肥満治療予防に有効なキナゾリン誘導体
US7816352B2 (en) 2005-03-10 2010-10-19 The Regents Of The University Of California Apoptosis inhibitors
EP1878727A4 (en) 2005-04-28 2013-11-13 Kyowa Hakko Kirin Co Ltd 2-AMINOQUINAZOLINE DERIVATIVES
PT1899322E (pt) 2005-06-28 2009-11-09 Sanofi Aventis Derivados de isoquinolina como inibidores de rho-cinase
PT1910333E (pt) 2005-07-26 2013-08-01 Sanofi Sa Derivados de isoquinolona substituída com piperidinilo como inibidores da rho-cinase
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
EP2044028B1 (en) 2006-01-27 2012-05-16 Fibrogen, Inc. Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
EP2079724B1 (en) 2006-07-20 2010-05-26 Amgen Inc. Substituted pyridone compounds and methods of use
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
JPWO2008050808A1 (ja) 2006-10-24 2010-02-25 協和発酵キリン株式会社 2−アミノキナゾリン誘導体
KR20090103903A (ko) 2006-12-27 2009-10-01 사노피-아벤티스 사이클로알킬아민 치환된 이소퀴놀론 및 이소퀴놀리논 유도체
MY150746A (en) 2006-12-27 2014-02-28 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
JP5405314B2 (ja) 2006-12-27 2014-02-05 サノフイ シクロアルキルアミン置換イソキノロン誘導体
WO2008086462A2 (en) 2007-01-11 2008-07-17 Wyeth AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
JP2010523529A (ja) 2007-04-06 2010-07-15 ノバルティス アーゲー プロテインキナーゼ調節剤としての2,6−ナフチリジン誘導体
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
NZ585226A (en) 2007-11-16 2012-08-31 Gilead Sciences Inc Inhibitors of human immunodeficiency virus replication
JPWO2009131173A1 (ja) 2008-04-23 2011-08-18 協和発酵キリン株式会社 2−アミノキナゾリン誘導体
EP2307400B1 (en) 2008-05-30 2014-04-23 Amgen, Inc Inhibitors of pi3 kinase
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
JP5335082B2 (ja) 2008-08-15 2013-11-06 ビーエーエスエフ ソシエタス・ヨーロピア ナノスケールの有機固体粒子の製造方法
WO2010077613A1 (en) 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
KR20110120878A (ko) 2008-12-29 2011-11-04 포비어 파마수티칼스 치환된 퀴나졸린 화합물
US8546564B2 (en) 2009-04-07 2013-10-01 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
WO2011035416A1 (en) 2009-09-25 2011-03-31 Aegera Therapeutics Inc. Hsp90 modulating compounds, compositions, methods and uses
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
AR081960A1 (es) 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
CA2803890A1 (en) 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Antimicrobial agents
SG186821A1 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
AP2013006706A0 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
WO2012044090A2 (ko) 2010-09-29 2012-04-05 크리스탈지노믹스(주) 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물
KR20120038060A (ko) 2010-10-13 2012-04-23 롬엔드하스전자재료코리아유한회사 신규한 유기 전자재료용 화합물 및 이를 포함하는 유기 전계 발광 소자
AR084280A1 (es) 2010-12-17 2013-05-02 Hoffmann La Roche Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン, エルエルシー 複素環化合物およびその使用
SG194512A1 (en) 2011-04-21 2013-12-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9399645B2 (en) 2011-12-20 2016-07-26 Boehringer Ingelheim International Gmbh Inhibitors of HIV replication
CN105121418A (zh) 2012-04-20 2015-12-02 吉利德科学公司 苯并噻唑-6-基乙酸衍生物及其治疗hiv感染的用途
SI2822954T1 (sl) 2012-12-21 2016-07-29 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
EP2940019B1 (en) 2012-12-27 2018-03-28 Japan Tobacco Inc. SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR
EP2769722A1 (en) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
EP2769723A1 (en) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Compounds for use in inhibiting HIV capsid assembly
US9914709B2 (en) 2013-06-21 2018-03-13 Yale University Compositions and methods of treating HIV-1 infections using same
AU2015371255B2 (en) 2014-12-24 2018-09-27 Gilead Sciences, Inc. Fused pyrimidine compounds for the treatment of HIV
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
JP6356919B2 (ja) 2014-12-24 2018-07-11 ギリアード サイエンシーズ, インコーポレイテッド Hivの処置のためのイソキノリン化合物

Also Published As

Publication number Publication date
MD4650B1 (ro) 2019-09-30
CN107278201B (zh) 2020-05-19
SI3237398T1 (sl) 2019-04-30
TW202106667A (zh) 2021-02-16
CR20170281A (es) 2017-11-08
JP2018168181A (ja) 2018-11-01
ES2715507T3 (es) 2019-06-04
CY1124726T1 (el) 2022-07-22
KR102288855B1 (ko) 2021-08-11
ES2964395T3 (es) 2024-04-05
MY189761A (en) 2022-03-03
EP3237398A1 (en) 2017-11-01
EP3960735C0 (en) 2023-09-13
PH12017501191A1 (en) 2018-03-05
ES2900810T3 (es) 2022-03-18
EP4302830A2 (en) 2024-01-10
EP3521282A1 (en) 2019-08-07
KR20170131351A (ko) 2017-11-29
JP2018500358A (ja) 2018-01-11
MX2019009932A (es) 2019-10-02
LT3521282T (lt) 2021-11-25
PL3237398T3 (pl) 2019-05-31
IL253059B (en) 2019-10-31
UA117796C2 (uk) 2018-09-25
NZ733174A (en) 2018-12-21
EA202091115A1 (ru) 2021-01-29
US20190134035A1 (en) 2019-05-09
ECSP17039611A (es) 2017-07-31
CN111574464A (zh) 2020-08-25
BR102015032361A2 (pt) 2016-07-05
IL269635A (en) 2019-11-28
CN107278201A (zh) 2017-10-20
PL3960735T3 (pl) 2024-03-18
AU2015371198A1 (en) 2017-07-13
SG10202101143VA (en) 2021-03-30
MD20170070A2 (ro) 2017-12-31
US11304948B2 (en) 2022-04-19
US9730936B2 (en) 2017-08-15
EA201791256A1 (ru) 2018-04-30
MA48448A (fr) 2021-04-28
US10548898B2 (en) 2020-02-04
WO2016105564A8 (en) 2016-10-06
KR102049476B1 (ko) 2019-11-28
US20170354656A1 (en) 2017-12-14
HK1244001B (en) 2020-01-10
WO2016105564A1 (en) 2016-06-30
CL2017001675A1 (es) 2018-05-11
KR20190133068A (ko) 2019-11-29
CA2972021C (en) 2020-04-28
EP3960735A1 (en) 2022-03-02
EP3960735B1 (en) 2023-09-13
US20200360383A1 (en) 2020-11-19
IL253059A0 (en) 2017-08-31
DK3521282T3 (da) 2021-09-27
PH12017501191B1 (en) 2021-08-06
MX2017008521A (es) 2018-03-01
SA517381826B1 (ar) 2021-10-21
MX367574B (es) 2019-08-27
EP3237398B1 (en) 2018-12-19
TW201636328A (zh) 2016-10-16
SV2017005471A (es) 2018-01-18
TWI699355B (zh) 2020-07-21
JP6367489B2 (ja) 2018-08-01
IL269635B (en) 2021-04-29
US10206926B2 (en) 2019-02-19
PT3521282T (pt) 2021-11-29
TW202237569A (zh) 2022-10-01
EP3521282B1 (en) 2021-08-25
AU2015371198B2 (en) 2018-09-27
EA035746B1 (ru) 2020-08-05
HRP20211543T1 (hr) 2022-01-07
DOP2017000151A (es) 2017-09-15
EP4302830A3 (en) 2024-03-13
PL3521282T3 (pl) 2022-01-03
US20230043136A1 (en) 2023-02-09
HUE058296T2 (hu) 2022-07-28
BR102015032361B1 (pt) 2021-12-21
TWI770552B (zh) 2022-07-11
TR201903672T4 (tr) 2019-04-22
SI3521282T1 (sl) 2021-11-30
CO2017006214A2 (es) 2017-10-20
US20160250215A1 (en) 2016-09-01
SG11201705215PA (en) 2017-07-28
AR103252A1 (es) 2017-04-26
CA2972021A1 (en) 2016-06-30
PT3237398T (pt) 2019-03-06
PE20171306A1 (es) 2017-09-05
BR102015032361A8 (pt) 2021-08-31

Similar Documents

Publication Publication Date Title
CU20170089A7 (es) Derivados de quinazolina utilizados para tratar el vih
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
EA201791304A1 (ru) Производные изохинолина для лечения вич
SV2016005171A (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
CL2019001495A1 (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih.
MX2016014547A (es) Compuestos para tratar atrofia muscular espinal.
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
ECSP17069696A (es) Compuestos novedosos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
PE20151607A1 (es) Formulaciones de compuestos organicos
CL2017001539A1 (es) Compuestos indenil, composiciones farmacéuticas y sus usos médicos de los mismos
UY36464A (es) Compuestos de quinazolina